Case Study | Acute Coronary Syndrome
How AcceleTrial compressed feasibility timelines for a global ACS trial with an innovative LDL-lowering drug, exceeding the sponsor's site targets and turnaround expectations.
Identifying sites with cardiovascular expertise, patient access, and operational readiness for an ACS study.
Communicating with a large number of sites and executing study documents within a compressed schedule.
Activating sites quickly to prevent downstream delays in the overall study schedule.
Using AcceleTrial, LINEA identified 65 sites with cardiovascular trial expertise. Feasibility and CDAs were completed in 2 to 3 days, exceeding the sponsor's expectations. All documents were collected at 50% the standard rate. Sites were evaluated against trial history, COVID-readiness, debarment, and clinical experience.
Exceeded sponsor target of 60, with full qualification against cardiovascular protocol criteria.
Feasibility and CDAs completed in 2 to 3 days, exceeding the sponsor's stated expectations.
46 LINEA sites selected for inclusion in the ACS study.